anti-Mouse (Murine) VEGFR2 antibody for Cytometry by Time of Flight

Recommended VEGFR2 Antibody (supplied by: Log in to see )

Antigen
Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) Antibodies
  • CD309
  • FLK1
  • VEGFR
  • VEGFR2
  • 6130401C07
  • Flk-1
  • Flk1
  • Krd-1
  • Ly73
  • VEGFR-2
  • sVEGFR-2
  • Vegfr-2
  • FLK-1
  • flk-1
  • vegfr-2
  • KDR
  • FLK/KDR
  • flk1
  • flk1b
  • kdrb
  • si:busm1-205d10.1
  • si:ch211-254j6.1
  • si:ch211-278f21.4
  • wu:fc31a09
  • kinase insert domain receptor
  • kinase insert domain protein receptor
  • vascular endothelial growth factor receptor kdr-like
  • kinase insert domain receptor (a type III receptor tyrosine kinase)
  • KDR
  • Kdr
  • LOC100136647
  • kdr
Epitope
AA 20-762
62
59
58
42
24
23
21
21
20
16
16
15
15
12
10
10
9
9
8
7
7
7
7
7
6
6
6
6
5
5
5
5
5
4
4
4
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Mouse (Murine)
621
396
206
28
8
5
5
5
4
4
3
2
2
2
2
2
2
2
1
1
1
1
1
Host
Goat
556
145
59
3
2
1
1
Clonality
Polyclonal
Conjugate
This VEGFR2 antibody is un-conjugated
44
34
28
26
16
12
11
9
6
5
5
5
5
4
3
3
3
3
3
3
3
3
2
2
2
2
2
2
1
1
1
Application
Cytometry by Time of Flight (CyTOF), Flow Cytometry (FACS), Immunohistochemistry (IHC), Neutralization (Neut), Western Blotting (WB)
494
269
269
199
133
106
45
39
31
26
25
19
17
8
7
7
6
5
5
2
1
1
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

Submit your validation data for this product and get a full refund. I want to validate this product

Learn more

Available images

Catalog No. ABIN4899536
Contact our Customer Service for availability and price in your country.
Relevance Score ABIN Application Conjugate Host Isotype Epitope Supplier Clonality References Details
1 ABIN4899537 CyTOF FACS ICC Rat IgG1 AA 20-762 Log in to see 522302 1

General

Antigen Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) Antibodies
Epitope AA 20-762
(62), (59), (58), (42), (24), (23), (21), (21), (20), (16), (16), (15), (15), (12), (10), (10), (9), (9), (8), (7), (7), (7), (7), (7), (6), (6), (6), (6), (5), (5), (5), (5), (5), (4), (4), (4), (3), (3), (3), (3), (3), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity Mouse (Murine)
(621), (396), (206), (28), (8), (5), (5), (5), (4), (4), (3), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1)
Host Goat
(556), (145), (59), (3), (2), (1), (1)
Clonality
Polyclonal
Conjugate This VEGFR2 antibody is un-conjugated
(44), (34), (28), (26), (16), (12), (11), (9), (6), (5), (5), (5), (5), (4), (3), (3), (3), (3), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (1), (1), (1)
Application Cytometry by Time of Flight (CyTOF), Flow Cytometry (FACS), Immunohistochemistry (IHC), Neutralization (Neut), Western Blotting (WB)
(494), (269), (269), (199), (133), (106), (45), (39), (31), (26), (25), (19), (17), (8), (7), (7), (6), (5), (5), (2), (1), (1), (1), (1), (1)
Pubmed 37 references available
Supplier Log in to see

Product Details anti-VEGFR2 Antibody

Target Details VEGFR2 Application Details Handling References for anti-VEGFR2 antibody (ABIN4899536) Images
Specificity Detects mouse VEGF R2 in direct ELISAs and Western blots. In direct ELISAs, approximately 10 % cross-reactivity with recombinant human VEGF R2 is observed and less than 2 % cross-reactivity with recombinant mouse (rm) VEGF R1 and rmVEGF R3 is observed.
Purification Immunogen affinity purified
Sterility 0.2 μm filtered
Endotoxin Level <0.10 EU per 1 μg of the antibody by the LAL method.
Immunogen Mouse myeloma cell line NS0-derived recombinant mouse VEGF R2, Ala20-Glu762, Accession # P35918
Isotype IgG
Plasmids, Primers & others

Target Details VEGFR2

Product Details anti-VEGFR2 Antibody Application Details Handling References for anti-VEGFR2 antibody (ABIN4899536) Images back to top
Antigen
Alternative Name VEGF R2/KDR (KDR Antibody Abstract)
Background Alternative Names: CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGFR, VEGFR2, VEGFR-2
Gene ID 3791
UniProt P35918
Pathways RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling

Application Details

Product Details anti-VEGFR2 Antibody Target Details VEGFR2 Handling References for anti-VEGFR2 antibody (ABIN4899536) Images back to top
Application Notes Western Blot 0.1 μg/mL
Flow Cytometry 2.5 μg/10^6 cells
Immunohistochemistry 5-15 μg/mL
Neutralization 0.1-0.3 μg/mL
CyTOF-ready
Restrictions For Research Use only

Handling

Product Details anti-VEGFR2 Antibody Target Details VEGFR2 Application Details References for anti-VEGFR2 antibody (ABIN4899536) Images back to top
Reconstitution Reconstitute at 0.2 mg/mL in sterile PBS.
Buffer Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Preservative Without preservative
Storage 4 °C,-20 °C,-80 °C
Storage Comment Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt,-20°C to -70°C as supplied. 1 month,2°C to 8°C under sterile conditions after reconstitution. 6 months,-20°C to -70°C under sterile conditions after reconstitution.
Expiry Date 12 months

References for anti-VEGFR2 antibody (ABIN4899536)

Product Details anti-VEGFR2 Antibody Target Details VEGFR2 Application Details Handling Images back to top
Product cited in:

Langen, Pitulescu, Kim, Enriquez-Gasca, Sivaraj, Kusumbe, Singh, Di Russo, Bixel, Zhou, Sorokin, Vaquerizas, Adams: "Cell-matrix signals specify bone endothelial cells during developmental osteogenesis." in: Nature cell biology, Vol. 19, Issue 3, pp. 189-201, 2017 Method employed by authors: Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Wu, Zhao, Fu, Yin, Song, Zhang, Zhao, Zhang: "Retinoic acid-induced upregulation of miR-219 promotes the differentiation of embryonic stem cells into neural cells." in: Cell death & disease, Vol. 8, Issue 7, pp. e2953, 2017 Method employed by authors: Western Blotting (WB) (Sample species: Mouse (Murine)).

Kim, Park, Bae, Park, Kim, Lee, Song, Chung, Lim, Kubota, Hong, He, Augustin, Oliver, Koh: "Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma." in: The Journal of clinical investigation, Vol. 127, Issue 10, pp. 3877-3896, 2017 Method employed by authors: Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Ulvmar, Martinez-Corral, Stanczuk, Mäkinen: "Pdgfrb-Cre targets lymphatic endothelial cells of both venous and non-venous origins." in: Genesis (New York, N.Y. : 2000), Vol. 54, Issue 6, pp. 350-8, 2016 Method employed by authors: Immunohistochemistry (IHC), Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Hou, Nilchi, Li, Gangaraju, Jiang, Aylsworth, Monette, Slinn: "Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage." in: Scientific reports, Vol. 5, pp. 7890, 2015 Method employed by authors: Biochemical Assay (BCA), Biochemical Assay (BCA) (Sample species: Rat (Rattus)).

Rama, Dubrac, Mathivet, Ní Chárthaigh, Genet, Cristofaro, Pibouin-Fragner, Ma, Eichmann, Chédotal: "Slit2 signaling through Robo1 and Robo2 is required for retinal neovascularization." in: Nature medicine, Vol. 21, Issue 5, pp. 483-91, 2015 Method employed by authors: Immunohistochemistry (IHC), Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Plein, Calmont, Fantin, Denti, Anderson, Scambler, Ruhrberg: "Neural crest-derived SEMA3C activates endothelial NRP1 for cardiac outflow tract septation." in: The Journal of clinical investigation, Vol. 125, Issue 7, pp. 2661-76, 2015 Method employed by authors: Immunohistochemistry (IHC), Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Aspelund, Tammela, Antila, Nurmi, Leppänen, Zarkada, Stanczuk, Francois, Mäkinen, Saharinen, Immonen, Alitalo: "The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel." in: The Journal of clinical investigation, Vol. 124, Issue 9, pp. 3975-86, 2015 Method employed by authors: Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Goldman, Han, Sourisseau, Sourrisseau, Dziedzic, Hamou, Corneo, DSouza, Sato, Kotton, Bissig, Kalir, Jacobs, Evans, Evans, Gouon-Evans: "KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development." in: Cell stem cell, Vol. 12, Issue 6, pp. 748-60, 2014 Method employed by authors: Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Song, Herzog, Sheng, Fu, McDaniel, Chen, Ruan, Xia: "Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma." in: Cancer research, Vol. 73, Issue 24, pp. 7254-64, 2013 Method employed by authors: Western Blotting (WB), Western Blotting (WB) (Sample species: Human).

Fantin, Vieira, Plein, Maden, Ruhrberg: "The embryonic mouse hindbrain as a qualitative and quantitative model for studying the molecular and cellular mechanisms of angiogenesis." in: Nature protocols, Vol. 8, Issue 2, pp. 418-29, 2013 Method employed by authors: Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Carmi, Dotan, Rider, Kaplanov, White, Baron, Abutbul, Huszar, Dinarello, Apte, Voronov: "The role of IL-1β in the early tumor cell-induced angiogenic response." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 190, Issue 7, pp. 3500-9, 2013

Benedito, Rocha, Woeste, Zamykal, Radtke, Casanovas, Duarte, Pytowski, Adams: "Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling." in: Nature, Vol. 484, Issue 7392, pp. 110-4, 2012 Method employed by authors: ELISA (ELISA), ELISA (ELISA) (Sample species: Mouse (Murine)).

Schreurs, Houston, May, Cipolla: "The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 26, Issue 1, pp. 355-62, 2012 Method employed by authors: In vivo Studies (in vivo), In vivo Studies (in vivo) (Sample species: Rat (Rattus)).

Sun, Li, Massena, Kutschera, Padhan, Gualandi, Sundvold-Gjerstad, Gustafsson, Choy, Zang, Quach, Jansson, Phillipson, Abid, Spurkland, Claesson-Welsh: "VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd." in: The Journal of experimental medicine, Vol. 209, Issue 7, pp. 1363-77, 2012 Method employed by authors: Western Blotting (WB), Western Blotting (WB) (Sample species: Mouse (Murine)).

Efe, Hilcove, Kim, Zhou, Ouyang, Wang, Chen, Ding: "Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy." in: Nature cell biology, Vol. 13, Issue 3, pp. 215-22, 2011 Method employed by authors: Immunocytochemistry (ICC), Immunocytochemistry (ICC) (Sample species: Mouse (Murine)).

Sawamiphak, Seidel, Essmann, Wilkinson, Pitulescu, Acker, Acker-Palmer: "Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis." in: Nature, Vol. 465, Issue 7297, pp. 487-91, 2010 Method employed by authors: Immunoprecipitation (IP), Immunoprecipitation (IP) (Sample species: Mouse (Murine)).

Tammela, Zarkada, Wallgard, Murtomäki, Suchting, Wirzenius, Waltari, Hellström, Schomber, Peltonen, Freitas, Duarte, Isoniemi, Laakkonen, Christofori, Ylä-Herttuala, Shibuya, Pytowski, Eichmann et al.: "Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. ..." in: Nature, Vol. 454, Issue 7204, pp. 656-60, 2008 Method employed by authors: Immunohistochemistry (IHC), Immunohistochemistry (IHC) (Sample species: Mouse (Murine)).

Dombrowski, Deshpande, Dingwall, Leichliter, Leibson, Luciano: "Chronic hydrocephalus-induced hypoxia: increased expression of VEGFR-2+ and blood vessel density in hippocampus." in: Neuroscience, Vol. 152, Issue 2, pp. 346-59, 2008 Method employed by authors: Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Frozen Sections) (IHC (fro)) (Sample species: Dog (Canine)).

Fernandez, Rodriguez, Huang, Chora, Fernandes, Mumaw, Cruz, Pollok, Cristina, Price, Ferkowicz, Scadden, Clauss, Cardoso, Carlesso: "Tumor necrosis factor-alpha and endothelial cells modulate Notch signaling in the bone marrow microenvironment during inflammation." in: Experimental hematology, Vol. 36, Issue 5, pp. 545-558, 2008 Method employed by authors: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) (Sample species: Mouse (Murine)).

Images

Product Details anti-VEGFR2 Antibody Target Details VEGFR2 Application Details Handling References for anti-VEGFR2 antibody (ABIN4899536) back to top
Supplier Images
Neutralization (Neut) image for anti-Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) (AA 20-762) antibody (ABIN4899536) VEGF R2/KDR/Flk-1 Inhibition of VEGF-dependent Cell Proliferation and Neutralization ...
Immunohistochemistry (IHC) image for anti-Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) (AA 20-762) antibody (ABIN4899536) VEGF R2/KDR/Flk-1 in Mouse Embryo. VEGF R2/KDR/Flk-1 was detected in immersion fixed ...
Immunohistochemistry (IHC) image for anti-Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) (AA 20-762) antibody (ABIN4899536) VEGF R2 in Mouse Kidney Tissue. VEGF R2 was detected in acetone fixed cryosections of...